(Q53393758)

English

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Jeeyun Lee

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Se Hoon Park

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Heung-Moon Chang

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jun Suk Kim

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Myung Ah Lee

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Joung Soon Jang

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Hei Cheul Jeung

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jung Hun Kang

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Hyun Woo Lee

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Dong Bok Shin

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Hye Jin Kang

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jong-Mu Sun

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Joon Oh Park

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Young Suk Park

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Won Ki Kang

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Ho Yeong Lim

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

20 December 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

181-188

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Nationwide cancer incidence in Korea, 2003-2005.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of chemotherapy in cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of erlotinib in patients with advanced biliary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Unresectable hilar cholangiocarcinoma: multimodality treatment with percutaneous and intraluminal plus external radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined modality treatment in unresectable extrahepatic biliary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular targeted therapy of biliary tract cancer--results of the first clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970301-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70301-1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22192731%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53393758&oldid=1417661469"